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Background and objectives
Standard care for locally advanced squamous cell carcinoma of
the head and neck (HNSCC) is cisplatin-based
chemoradiotherapy (C-CRT). Use of intensity modulated
radiotherapy (IMRT) increases the accuracy of RT delivery,
reducing toxicity to normal tissue and potentially allowing
higher doses to be delivered to the tumour. However, despite
aggressive primary management many patients with high risk
disease develop recurrence.
The PARP-1 inhibitor olaparib inhibits DNA damage repair and
may potentiate the anti-tumour activity of C-CRT. Preclinical
data demonstrate potent radio-sensitisation but the optimal
dosing schedule to enhance anti-tumour activity, whilst
allowing normal tissue recovery, has not been investigated
clinically.
ORCA-2 is a dose finding phase I study which will use a two
dimensional dose escalation design to determine the
maximum tolerated dose and schedule (MTD) of olaparib +
cisplatin-based chemoradiotherapy (C-CRT). The total
exposure to olaparib will be escalated both by increasing the
dose over a fixed duration and increasing duration of a fixed
dose.
An expansion cohort of 10-15 patients will be recruited at the
MTD in order to define the recommended phase II dose and
schedule (RP2D). If more than one MTD is defined, up to two
cohorts will be chosen for expansion.
Expected recruitment for the trial is between 30 and 50
patients from up to 6 sites across the UK.
Endpoints
Primary Endpoint:
• Occurrence of Dose Limiting Toxicities (DLTs) during the
DLT review period (treatment phase to 6 weeks post
completion of C-CRT).
Secondary Endpoints: 
• Frequency & severity of adverse events
• Time to loco-regional & any progression (TLP and TTP),
• Progression free survival (PFS),
• Overall survival (OS),
• Best overall response,
• Exploratory translational PK / PD endpoints
Trial Contact: ctc.orca2@ucl.ac.uk CI Contact: martin.forster@ucl.ac.uk
Trial Design
Key Inclusion Criteria
• Histologically confirmed high risk locally advanced HNSCC
(TNM staging Tany N2/3 M0, bulky T3 or T4 Nany M0)
• WHO performance status 0 or 1
• Aged ≥18 years of age
• Adequate major organ function
• Patients must be able to swallow olaparib tablets
• Able to give informed consent
Key Exclusion Criteria
• Head and neck cancers of the following types:
o Nasopharyngeal and paranasal sinus tumours
o Oral squamous cell carcinomas (tumours of the oral
cavity)
o Low risk Human Papilloma Virus (HPV) positive
oropharyngeal tumours (tonsillar and tongue base
tumours)
• Confirmed distant metastatic disease
• Previous chemotherapy or radiotherapy for the treatment of
HNSCC tumour
• Previous therapy with a PARP inhibitor
• Pre-existing gastrointestinal disorders that may interfere with
the delivery or absorption of olaparib
• The current use of drugs which are known to inhibit or
induce CYP3A4
• Resting ECG with QTc >480 msec or family history of long QT
syndrome
• Contraindications to cisplatin treatment
• Assessment of target inhibition in peripheral mononuclear
blood cells (PBMCs)
• Evaluation of other pharmacodynamic (PD) and predictive
biomarkers in PBMCs, archival tumour tissue, and snap
frozen tumour tissue
• Measurement of plasma concentrations of olaparib for
correlation with PD markers
• Evaluation of plasma circulating biomarkers
• Enumeration of circulating tumour cells.
• Functional multi-parametric MRI assessments in expansion
cohorts
Exploratory Biological Studies
All patients will receive the same dose of cisplatin + IMRT. Olaparib
will be escalated by increasing both the dose (50, 100, 150 & 200 mg
bd) and duration (3, 4 & 5 days). A Baysian dose escalation method,
the Product of Independent Beta Probabilities Escalation (PIPE), is
being used to guide dose escalation, which incorporates a target
toxicity level of 33%. This design allows flexibility and adaptability to
provide better estimates of the recommended dose-duration
combinations for further investigation than a standard 3+3 design.
Current Status (as at April 2016)
Number of site activated: 1
First patient entered into the trial on 04/Feb/2016
Recruitment: 1 patient
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Figure 2: Olaparib dose escalation scheme.
The dose of olaparib per day will be increased over a fixed number of days (dotted arrows) and the number of 
days increased for a fixed dose of olaparib per day (solid arrows).  Approximately equivalent doses have been 
grouped into dose bands.  The small red oval indicates the cohort number.
Dose Escalation Scheme
Treatment
Week 0: Patients receive olaparib alone for the purposes of the
exploratory biological studies. The weekly dose and schedule is
assigned according to dose escalation scheme.
Weeks 1-7 (olaparib + C-CRT): Combination treatment is
administered in a weekly schedule over 7 weeks as follows:
• Oral olaparib taken twice daily as per week 0
• Cisplatin 35 mg/m2 IV day 1 every week (total dose 245 mg/m2)
• IMRT is delivered on days 1-5 each week at a fixed total dose of 70
Gy in fractions. IMRT on day 1 of each week should begin after
completion of cisplatin administration.
Figure 1: Schematic of treatment plan and DLT window
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